For adjusting the composition and method of NK cytoactives

For adjusting the composition and method of NK cytoactives

  • CN 103,467,602 B
  • Filed: 07/01/2004
  • Issued: 04/10/2018
  • Est. Priority Date: 07/02/2003
  • Status: Active Grant
First Claim
Patent Images

1. a kind of antibody being combined with human inhibitory killing Ig samples acceptor (KIR) KIR2DL1 and KIR2DL2/3, and it is describedAntibody in the NK cells for expressing one of at least described two different human inhibitory KIR acceptors can in and KIR2DL1 andThe inhibitory action of the NK cytotoxicities of KIR2DL2/3 mediations, and wherein described antibody includes:

  • The heavy chain CDR1 being made up of amino acid sequence GFSFTPYGVH,The heavy chain CDR2 being made up of amino acid sequence VIWSGGNTDYNAAFIS,The heavy chain CDR3 being made up of amino acid sequence NPRPGNYPYGMDY,The light chain CDR1 being made up of amino acid sequence KASENVVTYVS,The light chain CDR2 being made up of amino acid sequence GASNRYT, andThe light chain CDR3 being made up of amino acid sequence GQGYSYPYT.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×